Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSV | O60911 | 2/20 | 0.44 |
| ▸ | CTSL | P07711 | 2/20 | 0.44 |
| ▸ | GABRP | O00591 | 1/20 | 0.42 |
| ▸ | GABRD | O14764 | 1/20 | 0.42 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.42 |
| ▸ | IDO1 | P14902 | 1/20 | 0.42 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.42 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.42 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.42 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.42 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.42 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.42 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.42 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.42 |
| ▸ | GABRE | P78334 | 1/20 | 0.42 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.42 |
| ▸ | GABRG1 | Q8N1C3 | 1/20 | 0.42 |
| ▸ | GABRG3 | Q99928 | 1/20 | 0.42 |
| ▸ | GABRQ | Q9UN88 | 1/20 | 0.42 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10198620 | 0.81 | AKT2 (0.39) | TLR8TLR7TLR9 | |
| SCHEMBL23903817 | 0.80 | MPL (0.43) | CTSVCTSLGABRPGABRDGABRA1 | |
| SCHEMBL199210 | 0.79 | LPL (0.52) | LPLLIPGHTTXIAPNPC1 | |
| SCHEMBL31108179 | 0.78 | HTR1A (0.54) | CTSVCTSLGABRPGABRDGABRA1 | |
| SCHEMBL4323287 | 0.78 | HTR1A (0.54) | CTSVCTSLGABRPGABRDGABRA1 | |
| SCHEMBL15274972 | 0.77 | HTR7 (0.47) | — | |
| SCHEMBL262356 | 0.76 | CTSV (0.46) | CTSVCTSLGABRPGABRDGABRA1 | |
| SCHEMBL262783 | 0.76 | CTSV (0.41) | CTSVCTSLGABRPGABRDGABRA1 | |
| SCHEMBL28229315 | 0.75 | CTSV (0.55) | CTSVCTSLGABRPGABRDGABRA1 | |
| SCHEMBL11515483 | 0.74 | PSMB5 (0.49) | LPLLIPGHSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220169756-A1 | BIARYL HYDROXYTHIOPHENE GROUP IV TRANSITION METAL POLYMERIZATION WITH CHAIN TRANSFER CAPABILITY | DOW GLOBAL TECHNOLOGIES LLC (US) | 2022-06-02 | — | — | US | disclosed |
| US-20220025085-A1 | BIARYL HYDROXYTHIOPHENE GROUP IV TRANSITION METAL POLYMERIZATION CATALYSTS WITH CHAIN TRANSFER CAPABILITY | DOW GLOBAL TECHNOLOGIES LLC (US) | 2022-01-27 | — | — | US | disclosed |
| US-11168161-B2 | Biaryl phenoxy group IV transition metal catalysts for olefin polymerization | DOW GLOBAL TECHNOLOGIES LLC (US) | 2021-11-09 | — | — | US | disclosed |
| US-20200157254-A1 | BIARYL PHENOXY GROUP IV TRANSITION METAL CATALYSTS FOR OLEFIN POLYERMIZATION | DOW GLOBAL TECHNOLOGIES LLC (US) | 2020-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220025085-A1 | BIARYL HYDROXYTHIOPHENE GROUP IV TRANSITION METAL POLYMERIZATION CATALYSTS WITH CHAIN TRANSFER CAPABILITY | TRMT1, GFPT1, BCAT1 | CTSV 1467/4885CTSL 3786/4885GABRP 1513/4885 |
| US-11168161-B2 | Biaryl phenoxy group IV transition metal catalysts for olefin polymerization | PPOX, LIG4, PARG | CTSV 332/4885CTSL 2089/4885GABRP 980/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.